The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004).
 
Katherine Cynthia Fuh
Honoraria - aravive
Consulting or Advisory Role - Aravive; Myriad Genetics
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - AVB-S6-500
 
Thomas J. Herzog
Leadership - GOG Partners
Consulting or Advisory Role - Aravive; AstraZeneca; Caris MPI; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; Merck; Roche/Genentech
 
Kathleen N. Moore
Honoraria - Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - Abbvie; Aravive; AstraZeneca (Inst); Eisai; Genentech/Roche; Immunogen; Merck; Mersana (Inst); Myriad Genetics; Pfizer/EMD Serono; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
 
Tashanna K. N. Myers
No Relationships to Disclose
 
BJ Rimel
Honoraria - Genentech
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Deep 6 AI; Genentech/Roche; GlaxoSmithKline; Merck; Tesaro
 
Joyce F. Liu
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Genentech/Roche; GlaxoSmithKline; Mersana; Regeneron; Tesaro
Research Funding - 2X Oncology (Inst); Acetylon Pharmaceuticals (Inst); Agenus (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Regeneron (Inst); Surface Oncology (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck
(OPTIONAL) Uncompensated Relationships - Merck
 
Angeles Alvarez Secord
Honoraria - Aravive; Clovis Oncology; Eisai; Merck; Myriad Genetics; Tesaro/GSK
Consulting or Advisory Role - Aravive; Clovis Oncology; Eisai; Merck; Tesaro
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immutep (Inst); Merck (Inst); OncoQuest Pharmaceuticals (Inst); PharmaMar (Inst); Seagen (Inst); Tesaro (Inst); VBL Therapeutics (Inst)
(OPTIONAL) Uncompensated Relationships - GOG Foundation; OncoQuest Pharmaceuticals; Roche/Genentech; VBL Therapeutics
 
Erika P. Hamilton
Consulting or Advisory Role - Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Akeso Biopharma (Inst); Amgen (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Polyphor (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Thomas J. Reid
No Relationships to Disclose
 
Sharyn Nan Lewin
No Relationships to Disclose
 
Mary M Mullen
No Relationships to Disclose
 
Kathryn A. Mills
Stock and Other Ownership Interests - Epizyme; Pfizer
 
Randy Anderson
Employment - Aravive
Stock and Other Ownership Interests - Aravive
Consulting or Advisory Role - Captains Ventures, Inc.
 
Reshma A. Rangwala
Employment - Aravive
Leadership - Aravive
Patents, Royalties, Other Intellectual Property - Genmab